Literature DB >> 27681566

Geographical patterns of mesothelioma incidence and asbestos exposure in Lombardy, Italy.

Carolina Mensi1, Sara De Matteis, Dolores Catelan, Barbara Dallari, Luciano Riboldi, Angela Cecilia Pesatori, Dario Consonni.   

Abstract

BACKGROUND: Measuring malignant mesothelioma (MM) occurrence is a useful means to monitor the impact of past asbestos exposure and possibly identify new sources of asbestos exposure.
OBJECTIVES: Aim of this study is to describe the results of the MM registry of the Lombardy Region, North-West Italy, the most populated (currently, 10 million inhabitants) and industrialised Italian region.
METHODS: We extracted from the Lombardy Region Mesothelioma Registry (Registro Mesoteliomi Lombardia, RML) database all incident cases of MM (pleura, peritoneum, pericardium, and tunica vaginalis testis) with first diagnosis in 2000 through 2012. For each Province, we calculated crude and standardised incidence rates using Italy 2001, European, and world (Segi's) standard populations. To examine spatial patterns of MM occurrence across municipalities we drew maps of crude rates smoothed according to the Besag, York and Mollié (BYM) method.
RESULTS: We recorded 4442 MM cases (2850 in men and 1592 in women), representing about one fourth of MM cases occurring in Italy. Occupational exposure was more frequent in men (73.6%) than in women (38.2%). The crude regional rates were 4.7 per 100,000 person-years in men and 2.5 per 100,000 person-years in women. The highest rates were observed in the Pavia Province (crude rates: 8.7 per 100,000 in men and 5.3 and per 100,000 person-years in women).
CONCLUSIONS: This study documented high MM occurrence in both genders, attributable to extensive asbestos exposure in the past.

Entities:  

Keywords:  zzm321990 Mesothelioma incidencezzm321990 ; zzm321990 asbestoszzm321990 ; zzm321990 cancer registryzzm321990 ; zzm321990 geographical patternzzm321990

Mesh:

Substances:

Year:  2016        PMID: 27681566

Source DB:  PubMed          Journal:  Med Lav        ISSN: 0025-7818            Impact factor:   1.275


  6 in total

Review 1.  Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: a review.

Authors:  Alfonso García-Fadrique; Akash Mehta; Faheez Mohamed; Sanjeev Dayal; Tom Cecil; Brendan J Moran
Journal:  J Gastrointest Oncol       Date:  2017-10

2.  Clustering of malignant pleural mesothelioma in asbestos factories: a subgroup analysis in a 29-year follow-up study to identify high-risk industries in Taiwan.

Authors:  Lukas Jyuhn-Hsiarn Lee; Cheng-Kuan Lin; Chih-Hong Pan; Yawen Cheng; Yu-Yin Chang; Saou-Hsing Liou; Jung-Der Wang
Journal:  BMJ Open       Date:  2018-12-09       Impact factor: 2.692

3.  Peritoneal mesothelioma and asbestos exposure: a population-based case-control study in Lombardy, Italy.

Authors:  Dario Consonni; Cristina Calvi; Sara De Matteis; Dario Mirabelli; Maria Teresa Landi; Neil E Caporaso; Susan Peters; Roel Vermeulen; Hans Kromhout; Barbara Dallari; Angela Cecilia Pesatori; Luciano Riboldi; Carolina Mensi
Journal:  Occup Environ Med       Date:  2019-07-08       Impact factor: 4.402

4.  Systems Thinking About SARS-CoV-2.

Authors:  Rainer Johannes Klement
Journal:  Front Public Health       Date:  2020-10-28

5.  Spatial Analysis of Shared Risk Factors between Pleural and Ovarian Cancer Mortality in Lombardy (Italy).

Authors:  Giorgia Stoppa; Carolina Mensi; Lucia Fazzo; Giada Minelli; Valerio Manno; Dario Consonni; Annibale Biggeri; Dolores Catelan
Journal:  Int J Environ Res Public Health       Date:  2022-03-15       Impact factor: 3.390

6.  Asbestos Exposure in Patients with Malignant Pleural Mesothelioma included in the PRIMATE Study, Lombardy, Italy.

Authors:  Andrea Spinazzè; Dario Consonni; Francesca Borghi; Sabrina Rovelli; Andrea Cattaneo; Carolina Zellino; Barbara Dallari; Angela Cecilia Pesatori; Hans Kromhout; Susan Peters; Luciano Riboldi; Domenico Maria Cavallo; Carolina Mensi
Journal:  Int J Environ Res Public Health       Date:  2022-03-13       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.